Attorney Docket No. 1662/55002

· Chre		Attorney Doc	Ret 140. 1002/33002	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				
SUPPLEMEN	NTAL INFORMATION E STATEMENT	Docket Numb	Docket Number: 1662/55002	
Application Number 10/016,752	Filing Date October 30, 2001	Examiner Taylor V. Oh	Art Unit 1625	
Invention Title NOVEL CRYSTAL AND SOLVATE FORMS OF ONDANSETRON HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION		Inventors Ramy Lidor	Inventors Ramy Lidor-Hadas et al.	

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandra, VA 22313-1450 I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: Amendment

Comissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450 on Feb. 27, 7006

Signature:

Sir:

- In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance 1. with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
- 2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.

3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due the Commissioner is authorized to charge deposit account number 11-0600 for such fees.

Respectfully submitted,

Date: 2127/06

Craig L. Puckett Reg. No. 43,023

KENYON & KENYON LLP One Broadway New York, New York 10004 (212) 425-7200 (telephone) (212) 425-5288 (facsimile) CUSTOMER NUMBER 26646 Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known MAR 0 8 2006 plication Number 10/016.752 INFORMATION DISCLOS ling Date October 30, 2001 STATEMENT BY APPLICAN Ramy Lidor-Hadas et al. First Named Inventor 1625 (Use as many sheets as necessary) Examiner Name Taylor V. Oh Sheet of | 2 Attorney Docket Number 1662/55002

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Initials *	No.¹	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
		4,739,072	04-19-1988	Oxford et al.	
		4,783,478	11-08-1988	Wootton et al.	
		4,835,173	05-30-1989	Tyers	
		4,957,609	09-18-1990	Godfrey et al.	
		4,983,621	01-08-1991	Bunce et al.	
		5,478,949	12-26-1995	Bod et al.	
		5,629,333	05-13-1997	Young	
		5,712,302	01-27-1998	Young	
		5,854,270	12-29-1998	Gambhir	
		5,962,494	10-05-1999	Young	
		6,063,802	05-16-2000	Winterborn	
		6,388,091	05-14-2002	Lee et al.	* **
		2004/0019093	01-29-2004	Aronhime et al.	
		2005/0020655	01-27-2005	Molnar et al.	

FOREIGN PATENT DOCUMENTS				Ì		
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Applicant of Cited Document		T⁵
		EP 0 276 559 B1	08-03-1998	Tyers		
		EP 0 415 522 B1	03-06-1990	Collin		
		WO 02/36558 A2 (U.S. equivalent 2002/0107275)	05-10-2002	Lidor-Hadas et al.		
		WO 02/055492 A2 (U.S. equivalent 2002/0115707)	07-18-2002	Lidor-Hadas et al.		
		WO 03/090730 A1	11-06-2003	Ndzie et al.		

	والمراكبة والمراكبين والمراكبين والمراكبين والمراكب والمراكب والمراكب والمراكب والمراكب والمراكب والمراكب		y.v
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/016,752 INFORMATION DISCLOSURE Filing Date October 30, 2001 STATEMENT BY APPLICANT Airst Named Inventor Ramy Lidor-Hadas et al. MAR 0 8 2006 (Use as many sheets as necessity) rt Unit 1625 Examiner Name Taylor V. Oh Sheet Attorney Docket Number 1662/55002 PADEMAR

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		Pirttimaki, J., et al. "The Transformation of Anhydrate and Hydrate Forms of Caffeine at 100% RH and 0% RH, European Journal of Pharmaceutical Sciences, 1994, Vol. 1, pp. 203-208			
		lida, H., et al. "Intramolecular Cyclization of Enaminones Involving Arylpalladium Complexes. Synthesis of Carbazoles" J. Org. Chem. 1980, Vol. 45, pp. 2938-2942			
		European Pharmacopoeia 4.4, Ondansetron Hydrochloride Dihydrate" 2003, pp. 3489-91,			
		Harry G. Brittain (Ed.) (1999) "Polymorphism in Pharmaceutical Solids" Drugs and the Pharmaceutical Sciences Vol. 95, pp. 183-226, Marcel Dekker, Inc. New York, New York			
1		Byrn, S.R., et al. (Ed.) (1999) "Solid-State Chemistry of Drugs" Second Edition, pp. 59-67, SSCI, Inc. West Lafayette, Indiana			
		Bym, S.R., et al. (Ed.) (1982) "Solid-State Chemistry of Drugs" pp. 6-7, Academic Press, New York, New York			
		Threlfall, T.L., et al. "Analysis of Organic Polymorphs" The Analyst, 1995, Vol. 120, pp. 2435-2460			
•		Carless, J.E., et al. "Cortisone acetate crystals forms" <i>J. Pharm. And Pharmacology</i> , 1966 , Vol. 18, pp. 190S-197S			
		Chen, Chem Abstr., "Synthesis of Antiemetic Ondansetron" Chinese J. of Pharmaceuticals, 1993, 24(6), pp. 241-242 (Ch).			
		The United States Pharmacopeia (USP 27-NF22), 22 nd edition, First Supplement, April, 2004, pages 3030, 3075-3076			
		The United States Pharmacopeia (USP 27-NF22), 22 nd edition, Second Supplement, August, 2004, pages 3234, 3283-3285			
		The United States Pharmacopeia (USP 26-NF21), 21 st edition, The National Formulary, January, 2003, pages 1351-1352			
-		The Merck Index p. 6977 "Ondansetron", 1996			
		Kim, M. Y, et al. "An Efficient Process of Ondansetron Synthesis" <i>Heterocycles</i> , 1997 , Vol. 45, No. 10, p. 2041-2043	_		

1	Examiner	Date	
	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.